Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 21;35(12):3406–3420. doi: 10.1038/s41375-021-01295-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — A Oncoprint of commonly occurring myeloid mutations in 88 AML patients. B Bar graph demonstrating distribution of AML patients stratified based on European Leukemia Net (ELN) prognostic risk groups and LSC frequency. The cutoff for high vs low LSC frequency was 0.5% (the median value for entire cohort). C Kaplan–Meier overall and relapse-free survival curves of AML patients stratified based on high (≥0.5%) vs low (<0.5%) LSC frequency at diagnosis. D The frequency of immunophenotypic LSCs (CD45^dimSSc^lowLin^–CD90^–CD34⁺CD38^–) in consecutive diagnosis and relapse samples of 10 AML patients. Gray lines indicate no statistically significant change, while red lines indicate a significant difference between the two VAFs. E TP53 and FLT3-ITD mutations were significantly more common among patients with high LSC frequency as compared to patients with low LSC frequency at diagnosis. *p < 0.05, **p < 0.01.